Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.65 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.65 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.65 |
| ▸ | NAMPT | P43490 | 4/20 | 0.57 |
| ▸ | DPP4 | P27487 | 6/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255502 | 0.81 | DPP7 (0.66) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL25730373 | 0.81 | NAMPT (0.56) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL25258146 | 0.81 | DPP7 (0.66) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL10121085 | 0.81 | NAMPT (0.56) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL14048143 | 0.80 | DPP8 (0.54) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL10150901 | 0.80 | NOTUM (0.62) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL8206656 | 0.80 | NAMPT (0.65) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL17341937 | 0.79 | NAMPT (0.53) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL11401928 | 0.79 | DPP8 (0.53) | DPP7DPP9DPP8NAMPTDPP4 | |
| SCHEMBL22271499 | 0.79 | DPP9 (0.56) | DPP7DPP9DPP8NAMPTDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2013052369-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | DPP7 560/4885DPP9 804/4885DPP8 693/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | DPP7 268/4885DPP9 525/4885DPP8 285/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | DPP7 668/4885DPP9 1080/4885DPP8 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.